Sandu Pharmaceuticals Ltd (SANDUPHQ)

Loading page…

Sandu Pharmaceuticals Ltd (SANDUPHQ) · mywealthgrid

About

Sandu Pharmaceuticals Ltd operates in Pharmaceuticals within the Healthcare sector.

Face value: ₹10

Market cap

₹35 Cr

P/E

22.9×

P/B

0.8×

Dividend yield

4.9%

ROE

3.8%

ROCE

5.3%

Debt / equity

OPM

4.1%

EPS (TTM)

₹1.6

Book value

₹43.5

52-week high

—

52-week low

—

2,166 historical price candles were omitted because the exchange source has not been verified.

₹36.5+1.9%1Y

Quick read

rule-based

Pros

+Almost debt-free (debt/equity 0)
+Comfortable interest coverage of 22.6×
+Dividend yield of 4.9%

Cons

−Low return on equity of 3.8% (3-yr avg)
−Thin operating margin of 4.1%
−Modest revenue growth of 0.9% a year over the last 3 years
−Promoter holding fell 5.1 pts over the last year

Research score

Structured signal from quality, growth, valuation and momentum.

38/100

Business quality: 40
Growth: 3

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Screen this industry Compare top 5 side-by-side

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Torrent Pharmaceuticals LimitedTORNTPHARMTORNTPHARM	₹1,61,325 Cr	₹1,76,123 Cr	₹15,723 Cr	₹5,191 Cr	32.6%	₹2,181 Cr	15.3%	14.5%	27.1%	163
Zydus Lifesciences LimitedZYDUSLIFEZYDUSLIFE	₹1,14,284 Cr	₹1,26,053 Cr	₹28,592 Cr	₹8,316 Cr	31.2%	₹4,513 Cr	18.9%	23.4%	19.7%	212
Laurus Labs LimitedLAURUSLABSLAURUSLABS	₹1,07,176 Cr	₹1,09,573 Cr	₹7,270 Cr	₹2,034 Cr	26.1%	₹1,093 Cr	13.1%	21.3%	18.2%	263
Mankind Pharma LimitedMANKINDMANKIND	₹1,04,696 Cr	₹1,11,007 Cr	₹14,738 Cr	₹3,827 Cr	25.3%	₹2,068 Cr	13.6%	14.2%	12.5%	117
Aurobindo Pharma LimitedAUROPHARMAAUROPHARMA	₹97,389 Cr	₹1,05,065 Cr	₹34,935 Cr	₹7,085 Cr	20.3%	₹3,713 Cr	10.4%	14.7%	9.9%	252
Lupin LimitedLUPINLUPIN	₹92,866 Cr	₹98,777 Cr	₹29,967 Cr	₹9,538 Cr	31.5%	₹5,529 Cr	19.2%	34.2%	26.9%	181
Glenmark Pharmaceuticals LimitedGLENMARKGLENMARK	₹65,781 Cr	₹65,781 Cr	₹17,737 Cr	₹4,797 Cr	26.9%	₹1,496 Cr	8%	37.8%	0%	83
Alkem Laboratories LimitedALKEMALKEM	₹62,431 Cr	₹64,055 Cr	₹15,081 Cr	₹3,032 Cr	20.4%	₹2,158 Cr	16%	21.5%	17.8%	152
Biocon LimitedBIOCONBIOCON	₹60,413 Cr	₹75,238 Cr	₹17,321 Cr	₹3,536 Cr	20.4%	₹495 Cr	2.2%	3.9%	1.4%	85
Abbott India LimitedABBOTINDIAABBOTINDIA	₹56,901 Cr	—	₹4,310 Cr	₹921 Cr	27.3%	₹691 Cr	22.4%	44.1%	34.5%	110
Ipca Laboratories LimitedIPCALABIPCALAB	₹49,299 Cr	₹50,003 Cr	₹10,126 Cr	₹2,232 Cr	20.5%	₹1,310 Cr	12.3%	17.8%	15.2%	308
Gland Pharma LimitedGLANDGLAND	₹47,428 Cr	₹47,671 Cr	₹6,725 Cr	₹1,751 Cr	25.3%	₹1,129 Cr	16%	14.8%	10.5%	255

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Consolidated Standalone

Consolidated figures · ₹ crore

₹ Cr	Mar 2022	Mar 2023	Mar 2024	Mar 2025
	65	65	67	67
COGS	31	31	33	32
Gross profit	34	34	35	35
	—	32	32	32
Operating profit (EBITDA)	—	2	2	3
OPM %	—	3.8%	3.4%	4.1%
Depreciation	1	1	1	1
Interest	0	0	0	0
	0	0	0	0
Profit before tax	—	2	2	2
Tax	—	1	1	1
Tax %	—	31.5%	29.5%	28.2%
	2	2	1	2
PAT margin %	2.3%	2.3%	2.2%	2.3%
EPS (₹)	—	—	1.5	1.6
EPS adjusted (₹)	—	1.6	1.5	1.6
	—	—	53%	49.7%
Annual report	Annual report for Mar 2022	Annual report for Mar 2023	Annual report for Mar 2024	Annual report for Mar 2025

₹ Cr	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity capital	0	10	10	10
Reserves	—	30	31	32
	—	0	0	0
	17	15	12	14
Total equity & liabilities	17	54	52	56
	16	17	18	18
CWIP	—	0	0	0
Investments	—	10	10	11
	1	27	24	26
Total assets	17	54	52	56

₹ Cr	Mar 2023	Mar 2024	Mar 2025
	0	1	1
	1	-1	-0
	1	-1	-0
Net cash flow	1	-1	0
Free cash flow	-1	-1	0
CFO / Operating profit %	8.8%	33.2%	34.4%

Compounded sales growth

7 years: —
5 years: —
3 years: 1%
1 year: -0%

Compounded profit growth

7 years: —
5 years: —
3 years: 1%
1 year: 6%

Return on equity

7 years: —
5 years: —
3 years: 4%
Last year: 4%

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Consolidated Standalone

Consolidated figures

Ratio	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Margins
Gross margin %	52.3%	52.3%	51.6%	52.2%
EBITDA margin %	—	3.8%	3.4%	4.1%
EBIT margin %	—	3%	2.5%	3.1%
PAT margin %	2.3%	2.3%	2.2%	2.3%
Working capital
Receivable days	—	27	26	26
Inventory days	—	168	137	161
Payable days	—	98	47	51
NWC days	—	96	117	136
Leverage
Current ratio	—	1.84	2.1	2.18
Debt to EBITDA	—	0	0	0
Debt to equity	—	0	0	0
Interest coverage	-2.4	28.8	35.5	22.6
Asset turnover	3.86	1.21	1.28	1.21
Return ratios
Return on assets %	9%	2.8%	2.8%	2.8%
Return on capital employed %	—	5.7%	5.2%	5.3%
Return on equity %	—	3.9%	3.6%	3.7%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	52.41%	42.9%	42.9%	42.9%	42.9%	42.9%	42.9%	42.9%	42.9%	37.79%	37.79%	37.79%
FII	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%
Government	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	47.58%	57.09%	57.09%	57.09%	57.09%	57.09%	57.09%	57.09%	57.09%	62.2%	62.2%	62.2%
No. of shareholders	—	—	—	—	—	—	—	—	10,284	10,284	10,298	10,268

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

No fund holdings on record

No scheme among the 32 fund houses on record reported a position in Sandu Pharmaceuticals Ltd. Portfolios are published monthly by each AMC; coverage is still partial.

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

6

Final dividend4 Sept 2026 · ex-date₹1
Final dividend18 Sept 2025 · ex-date₹0.8
Final dividend19 Sept 2024 · ex-date₹0.8
Final dividend18 Sept 2023 · ex-date₹0.75
Dividend dividend23 Sept 2022 · ex-date₹0.75
Dividend dividend22 Sept 2021 · ex-date₹0.5

1

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

78 announcementsExport CSV

19 Aug 2026, 5:41 pmCompany Update

Announcement Under Regulation 30-Letter To Shareholder On Annual Report Weblink Whose Email Ids Are Not Registered With The Company/RTA

General PDF

19 Aug 2026, 5:38 pmOthers

Reg. 34 (1) Annual Report.

Reg. 34 (1) Annual Report PDF

19 Aug 2026, 5:33 pmAGM/EGM

Annual General Meeting To Be Held On 11Th September 2026 At 04:30 Pm Through Video Conferencing ('VC')/ Other Audio Visual Means (QAVM)

AGM PDF

14 Aug 2026, 12:24 pmCompany Update

Announcement under Regulation 30 (LODR)-Newspaper Publication

Newspaper Publication PDF

11 Aug 2026, 6:41 pmCompany Update

Approval Of Material Related Party Transactions Subject To Approval Of Shareholders

General PDF

11 Aug 2026, 6:38 pmCompany Update

Statement Of Deviation And Utilisation Of Funds For Q Ended 30.06.2026

Reg. 32 (1), (3) - Statement of Deviation & Variation PDF

11 Aug 2026, 6:15 pmCompany Update

Announcement under Regulation 30 (LODR)-Change in Management

Change in Management PDF

11 Aug 2026, 6:07 pmCompany Update

Intimation About The Date Of The Annual General Meeting

General PDF

Date	Category	Subject	Filing
19 Aug 2026, 5:41 pm	Company Update General	Announcement Under Regulation 30-Letter To Shareholder On Annual Report Weblink Whose Email Ids Are Not Registered With The Company/RTA	PDF
19 Aug 2026, 5:38 pm	Others Reg. 34 (1) Annual Report	Reg. 34 (1) Annual Report.

Loading announcements…

Ratio	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Margins
Gross margin %	52.3%	52.3%	51.6%	52.2%
EBITDA margin %	—	3.8%	3.4%	4.1%
EBIT margin %	—	3%	2.5%	3.1%
PAT margin %	2.3%	2.3%	2.2%	2.3%
Working capital
Receivable days	—	27	26	26
Inventory days	—	168	137	161
Payable days	—	98	47	51
NWC days	—	96	117	136
Leverage
Current ratio	—	1.84	2.1	2.18
Debt to EBITDA	—	0	0	0
Debt to equity	—	0	0	0
Interest coverage	-2.4	28.8	35.5	22.6
Asset turnover	3.86	1.21	1.28	1.21
Return ratios
Return on assets %	9%	2.8%	2.8%	2.8%
Return on capital employed %	—	5.7%	5.2%	5.3%
Return on equity %	—	3.9%	3.6%	3.7%

2 deals · 19 Mar 2024 – 19 Mar 2024

Date	Client	Type	Venue	Side	Quantity	Price	Value
19 Mar 2024	TRANS SCAN SECURITIES PVT LTD	Bulk	BSE	Buy	1,06,000	₹55.88	₹0.59 Cr
19 Mar 2024	DPS TRADELINK PRIVATE LIMITED	Bulk	BSE	Sell	1,04,061	₹55.85	₹0.58 Cr

1–2 of 2

1 / 1

Bulk deals are a client trading over 0.5% of the equity in a session, aggregated across their trades; block deals are single negotiated trades in the exchange’s block window. Each is reported by the exchange it was crossed on, so NSE and BSE rows are separate trades rather than the same trade twice.

Sandu Pharmaceuticals Ltd

About

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Compounded profit growth

Return on equity

Ratios

Ratio timeline

Shareholding

Quarterly record

F&O

Not in the F&O segment

Fund holders

No fund holdings on record

Documents

Announcements

Events

Dividends6

Board meetings1

Announcements

Ratio timeline

Not in the F&O segment

No fund holdings on record

Announcements

Dividends6

Board meetings1

Quarterly record

Annual reports

Bulk & block deals

Board and management

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Compounded profit growth

Return on equity

6

1

6

1